67 results about "Streptococcus suis" patented technology

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

The invention provides a streptococcus suis vaccine recombinant fusion protein and a preparation method and application thereof, the recombinant fusion protein is a recombinant protein formed by series fusion of B cell epitopes of Sao, SLY and PepO proteins of streptococcus suis, and the amino acid sequence of the fusion protein is as shown in SEQ ID NO.1. After four-week-old weaned piglets are immunized by the fusion expression protein for 28 days, 80% and 60% of challenge protection rates can be provided for challenge of streptococcus suis type 2 and type 9 virulent strains respectively. The invention has great potential for clinical prevention and control of streptococcus suis infection.

The invention provides a streptococcus suis polysaccharide protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The vaccine comprises a polysaccharide-protein conjugate formed by coupling streptococcus suis type 2 capsular polysaccharide and streptococcus suis type 2 recombinant protein. The preparation method comprises the following steps: S1, preparing streptococcus suis type 2 capsular polysaccharide; s2, preparing streptococcus suis type 2 recombinant protein; s3, activating polysaccharide; s4, combining the biotinylated polysaccharide with the recombinant protein containing the avidin structural domain to form a stable polysaccharide-protein conjugate; s5, removing unbound proteins; and S6, mixing the polysaccharide-protein conjugate with the oil-water emulsion in proportion. By optimizing a coupling technology and a vaccine preparation formula, the immunogenicity and the protection effect of the vaccine are improved, the safety and the broad-spectrum cross protection capability of the vaccine are remarkably enhanced, the complexity and the cost of a vaccine production process are reduced, and the vaccine has a good industrial application prospect and a good popularization value.

The invention discloses bacillus velezensis, a microbial preparation as well as a preparation method and application of the microbial preparation, and relates to the technical field of microorganisms. The bacillus velezensis strain is preserved in the China Center for Type Culture Collection, and is named as bacillus velezensis XNW-BLSYB1, the preservation number is CCTCC NO: M 2025721, the preservation time is April 8, 2025, and the 16S rDNA sequence of the bacillus velezensis strain is as shown in SEQID No.1. The bacillus velezensis strain has the advantages that the bacillus velezensis strain is named as bacillus velezensis XNW-BLSYB1; the spore formed by the bacillus velezensis XNW-BLSYB1 strain can survive at high temperature, and can inhibit the reproductive and respiratory syndrome virus and inhibit the activity of bacteria such as streptococcus suis, infectious actinobacillus pleuropneumoniae, clostridium perfringens, pasteurella multocida and escherichia coli.

The invention relates to a porcine bacterial polysaccharide-viral protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of animal vaccines. The vaccine takes porcine bacterial polysaccharide and virus protein as raw materials, and a polysaccharide-virus protein conjugate is formed through coupling of a biotin-avidin system; wherein the virus protein is selected from one of classical swine fever virus E2 protein, porcine circovirus type 2 Cap protein, porcine pseudorabies virus gD protein and the like, and the porcine bacterial polysaccharide is selected from one of streptococcus suis capsular polysaccharide, porcine pasteurella multocida capsular polysaccharide and the like. The vaccine can simultaneously induce an organism to generate a high-level IgG antibody aiming at porcine bacterium capsular polysaccharide and virus protein, so that synergistic immune protection on porcine bacterium and virus infection is realized, and a broad-spectrum cross immune effect is achieved.

The invention belongs to the technical field of biology, and particularly relates to a quintuple fluorescent PCR detection reagent for porcine respiratory pathogens and application of the quintuple fluorescent PCR detection reagent. The quintuple fluorescent PCR detection reagent disclosed by the invention can achieve the purpose of simultaneously identifying and detecting actinobacillus pleuropneumoniae, haemophilus parasuis, mycoplasma hyopneumoniae, pasteurella multocida and / or streptococcus suis, and has the advantages of simplicity, convenience and rapidness in operation, high accuracy, high sensitivity and good repeatability; the method has important significance on rapid and accurate detection and epidemic disease prevention and control of clinical porcine respiratory pathogens.

This invention discloses an antimicrobial peptide cAMP-1 derived from the intestinal microorganisms of wild rodents and its applications, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide cAMP-1 is shown in SEQ ID NO:1. The antimicrobial peptide cAMP-1 exhibits highly efficient, rapid, and safe antimicrobial activity against Streptococcus suis type II. It significantly inhibits bacterial growth even at low concentrations, with a minimum inhibitory concentration (MIC) of 16 µg / mL. Time-kinetic kinetics results show that the antimicrobial peptide can kill all Streptococcus suis type II within 30 min and 15 min at concentrations of 2×MIC and 4×MIC, respectively. Furthermore, within several times the effective concentration range, the peptide exhibits almost no hemolytic activity and low cytotoxicity within a safe dosage range, demonstrating its promising application as a novel anti-infective candidate drug.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention discloses application of elaifolin in preparation of a medicine for resisting streptococcus suis, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the elaifolin can efficiently inhibit and kill a plurality of serotype streptococcus suis and obviously inhibit or remove biological membranes of the streptococcus suis. The elaifolin can be applied to preparation of anti-streptococcus suis bacteriostasis and sterilization medicines, medicines for treating streptococcus suis infection and medicines for inhibiting or removing streptococcus suis biological membranes. According to the application disclosed by the invention, new medicinal value of the elaifolin is found, and a new prevention and treatment strategy is provided for streptococcus suis drug resistance and biofilm infection; the elaifolin can efficiently act on the multi-drug-resistant streptococcus suis, and a new direction is provided for relieving antibiotic drug resistance crisis.

The invention relates to the technical field of veterinary vaccines, in particular to streptococcus suis capsular polysaccharide as well as a preparation method and application thereof. The preparation method of the streptococcus suis capsular polysaccharide is high in specificity, convenient to operate, good in repeatability, high in yield and low in cost, the extraction cost of the streptococcus suis capsular polysaccharide is further reduced, and meanwhile the polysaccharide yield is effectively increased. When the streptococcus suis capsular polysaccharide prepared by the method is further used for preparing a streptococcus suis capsular polysaccharide vaccine, the prepared streptococcus suis capsular polysaccharide vaccine shows more slight clinical symptoms than a streptococcus suis whole-cell inactivated vaccine, and has better biological safety and an excellent challenge protection effect.

The application belongs to the field of microorganisms and particularly relates to a Streptococcus suis type 2 high-yield capsular polysaccharide strain and application. From 46 Streptococcus suis type 2 strains clinically isolated and identified by the applicant, a capsular polysaccharide high-yield strain is screened out, and the preservation number of the strain is CCTCC NO: M20242085. The applicant further explores and optimizes the process of the Streptococcus suis type 2 high-yield capsular polysaccharide, so that the original fermentation process, which pays attention to the purpose of bacterial growth and reproduction, is changed to be more conducive to the production of high-quality capsular polysaccharide, and the yield of the capsular polysaccharide is further improved. The method has good controllability and repeatability and is conducive to large-scale process production. The application has important significance for the commercial production of the Streptococcus suis type 2 high-yield capsular polysaccharide.

The invention relates to a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection method for streptococcus equi subsp. Zooepidemicus virulent strains causing swine streptococcosis, and belongs to the technical field of bacterial detection. The invention provides a primer probe group which can be used for simultaneously detecting M protein variable region genes (szm-variant) of streptococcus equi subsp.zooepidemicus, conserved genes (comB) in subsp.zooepidemicus and central nervous system infection related virulence genes (bifA) of streptococcus equi subsp.zooepidemicus through Taqman probe triple fluorescent quantitative PCR (Polymerase Chain Reaction), and is shown as SEQ ID NO.1-9 in a sequence table. The multiplex fluorescent quantitative PCR detection method for the streptococcus equi subsp. Zooepidemicus virulent strain causing the swine streptococcosis can complete nucleic acid amplification and result judgment within 1 hour. According to the detection method, the amplification result is judged through the threshold cycle number (Ct value), electrophoresis detection is not needed, and the problems of pollution, false positive and the like of an amplification product can be avoided. The detection method provided by the invention has the characteristics of simplicity, convenience and rapidness in operation, high specificity, high sensitivity and good stability.

The invention discloses a chicken intestinal bacteriophage source antibacterial peptide, and belongs to the technical field of biology. The antibacterial peptide (CGV-AMP-1) disclosed by the invention shows excellent effects of high efficiency, rapidness and safety on staphylococcus capitis and streptococcus suis type II; the antibacterial peptide (CGV-AMP-1) can inhibit the growth of bacteria at extremely low concentration (MIC 8 g / ml), and has strong bactericidal ability (MBC 32 g / ml); the time sterilization dynamics experiment proves that the bacteria can be completely killed within 120 minutes; meanwhile, the peptide is extremely high in safety, almost has no hemolytic activity in a range of several times of effective concentration, is extremely low in cytotoxicity, and shows huge potential as a novel anti-infection drug.

The invention is applicable to the technical field of bioengineering, and provides a streptococcus suis bacteriophage antibacterial protein Lys8387 as well as a preparation method and application thereof, and the amino acid sequence of the streptococcus suis bacteriophage antibacterial protein Lys8387 is shown as SEQ ID NO.2. A novel bacteriophage antibacterial protein capable of playing splitting and depolymerizing double activities on streptococcus suis is constructed through a genetic engineering technology, and the lyase is novel in sequence, shows strong bactericidal activity on multi-drug-resistant streptococcus suis, can be independently used or compounded with other substances for use, or can be prepared into an enzyme preparation, and can be used for preparing an antibacterial agent for multiple drug-resistant streptococcus suis. The compound not only has bactericidal activity on streptococcus suis, but also has a degradation effect on capsular polysaccharide of streptococcus suis, K2 type klebsiella pneumoniae and the like, and a thought is provided for preparing a medicine for preventing and treating diseases caused by infection of microorganisms such as streptococcus suis and the like.

The present invention relates to the field of bioengineering technology, and discloses a Streptococcus suis receptor bacterium for bacterial conjugation, a construction method and an application thereof. Type 1 Streptococcus suis NP4CIP is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee on February 27, 2025, at the deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, with a deposit number of CGMCC NO.33594 and a classification name of Streptococcus suis. Streptococcus suis The present invention adopts the above-mentioned Streptococcus suis receptor bacteria for bacterial conjugation and its construction method and application, and the constructed NP4CIP strain has good stability, can better maintain the integration and expression of drug-resistant genes, overcomes the growth defect of P1 / 7RF, and at the same time, the NP4CIP conjugate can be used for re-conjugation experiments, laying a foundation for the study of the horizontal transfer mechanism of drug-resistant genes, and providing a basis and inspiration for controlling the spread of bacterial resistance.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention discloses a general culture medium and a quadruple PCR (Polymerase Chain Reaction) detection method aiming at swine infectious arthritis pathogenic bacteria such as streptococcus suis, graisseria parasuis, swine erysipelothrix erysipelas and mycoplasma hyorhinis, and belongs to the field of molecular biology. Aiming at the problem that culture media are different, the invention optimizes a culture medium, realizes co-culture of four pathogenic bacteria and is used for subsequent multiple PCR bacterium enrichment, discloses a specific primer group aiming at pathogenic bacteria conserved genes and establishes a quadruple PCR detection method for synchronously identifying the four pathogenic bacteria. According to the co-culture and detection method disclosed by the invention, the problem of complexity caused by using multiple culture mediums and the problem of low efficiency of single PCR are solved, and the method has relatively high sensitivity and specificity and has a wide application prospect in clinical mixed infection detection.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The invention provides a streptococcus suis serotype 2 virulent strain resistant to multiple antibiotics and application, and belongs to the technical field of vaccine preparation, the streptococcus suis serotype 2 resistant to multiple antibiotics is preserved in China Center for Type Culture Collection on December 6, 2024, the preservation number is CCTCC NO: M20242747, the classification name is streptococcus suis serotype 2 S068, the prepared streptococcus suis serotype 2 polysaccharide conjugate vaccine is applied, and the streptococcus suis serotype 2 polysaccharide conjugate vaccine can be used for preparing the streptococcus suis serotype 2 polysaccharide conjugate vaccine. The protection rate is higher, and good adaptability, high efficiency and safety in a complex clinical environment are shown.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and a method for detecting a streptococcus suis drug-resistant gene and application of the primer, nucleotide sequences of the primer are shown as SEQ ID NO.1-SEQ ID NO.2. The detection primer has specificity, and accuracy and reliability of the detection primer can be ensured.

The invention provides a dual fluorescent quantitative PCR (polymerase chain reaction) kit for simultaneously detecting streptococcus pasteurii and streptococcus suis, and belongs to the field of bacterial detection. The kit comprises a primer pair and a probe. The primer pair and the probe aiming at the streptococcus pasteurii comprise SP-3230F, SP-3230R and SP-probe, and the nucleotide sequences of the primer pair and the probe are as shown in SEQ ID NO: 1-3; the primer pair and the probe aiming at the streptococcus suis comprise SS-recNF, SS-recNR and SS-probe, and the nucleotide sequences of the primer pair and the probe are as shown in SEQ ID NO: 4-6. The kit provided by the invention has the advantages of high sensitivity, high specificity, low pollution and real-time detection, and provides reliable technology and product for early diagnosis, monitoring, early warning, prevention and treatment of clinical swine streptococcosis in farms.

The invention belongs to the technical field of microorganisms. The invention provides bacillus subtilis QXKL-3, a preparation based on the bacillus subtilis QXKL-3 and application of the bacillus subtilis QXKL-3 in inhibition of streptococcus suis type 2. The strain is preserved in the China General Microbiological Culture Collection Center, the preservation date is September 11, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28419. The cell-free supernate of the bacillus subtilis QXKL-3 provided by the invention has efficient antibacterial activity on streptococcus suis type 2, and the antibacterial effect of the cell-free supernate is obviously higher than that of penicillin; meanwhile, even at the temperature of 100 DEG C, the efficient antibacterial property on the streptococcus suis type 2 can still be kept; and the antibacterial activity is still stable under long-time preservation.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The invention pertains to a stable vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine. The invention also pertains to a vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine for use in a method for protecting pigs against a pathogenic infection of S. suis bacteria. The invention also pertains to methods of preparing the vaccine formulation, preferably wherein the method comprises a step of lyophilizing the vaccine formulation.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide for regulating and controlling micro-ecology as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni), genital tract pathogenic bacteria (such as staphylococcus aureus, gardnebacterium and enterococcus faecalis) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

This invention discloses an engineered strain of Streptococcus suis Δ07335-hSLY (classification name: Streptococcus suis Δ07335-hSLY, deposit date: May 13, 2026, deposit number: CCTCC NO: M2026937), its construction method, and applications, relating to the fields of microbial genetic engineering and drug screening technology. This invention uses Streptococcus suis SC19 strain as the starting strain and obtains the engineered strain SC19Δ07335 by knocking out the 07335 gene in its genome using homologous recombination technology. Compared with the starting strain SC19, the expression level of the hemolysin SLY gene in this engineered strain is significantly upregulated, increasing the success rate of the hemolysis test in the culture supernatant from 30% to 100%. Simultaneously, the expression of the capsular polysaccharide synthesis gene CPS is downregulated, the capsule becomes thinner, and the in vivo virulence is significantly reduced. The anti-hemolytic active compound screening system established based on this engineered strain is stable and reliable, and compounds with anti-SLY activity, such as baicalin, have been successfully screened. Animal experiments have verified that the survival rate of mice in the medium and high dose treatment groups of baicalin reached 100%.

The application provides a kit for detecting penicillin and amoxicillin resistance of streptococcus suis and application thereof, and belongs to the technical field of molecular biology detection. The kit comprises a primer pair and AlwNI restriction endonuclease; the primer pair comprises primers PBP1a-2083F and PBP1a-2083R, and the sequences are shown in SEQ ID NO:1 and SEQ ID NO:2 respectively. The kit is used for detecting penicillin and amoxicillin resistance of streptococcus suis, has the advantages of high specificity, high sensitivity, low detection cost and low technical requirement, and provides reliable technology for monitoring penicillin and amoxicillin resistance of streptococcus suis in clinic.